Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) — The “U.S. Peptide Therapeutics (Retail Side) Market Size, Share & Trends Analysis Report by Peptide Type, by Indication, by Route of Administration, by Therapeutics Type, by Distribution Channel, and Segment Forecasts, 2025-2033” report has been added to ResearchAndMarkets.com’s offering.
The U.S. peptide therapeutics (retail side) market size was estimated at USD 103.66 billion in 2024 and is expected to reach USD 336.12 billion by 2033, growing at a CAGR of 12.77% from 2025 to 2033.
The increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, highlights the need for affordable and effective treatment options. In addition, the increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, underscores the need for affordable and effective treatment options.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
- COVID-19’s impact and how to sustain in these fast-evolving markets
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 165 |
| Forecast Period | 2024 – 2033 |
| Estimated Market Value (USD) in 2024 | $103.66 Billion |
| Forecasted Market Value (USD) by 2033 | $336.12 Billion |
| Compound Annual Growth Rate | 12.7% |
| Regions Covered | United States |
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
2.1. U.S. Peptide Therapeutics (Retail Side) Market
2.1.1. Market Snapshot
2.1.2. Segment Snapshot
2.1.2.1. Therapeutics type & indication segment outlook
2.1.2.2. Route of administration & distribution channel segment outlook
2.1.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Regulatory Framework
3.5. Business Environment Analysis Tools
3.5.1. Industry Analysis – Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
3.6. Pricing Analysis in Online vs. Offline Channels
3.7. Consumer Awareness Trends for Peptide Therapies
3.8. Direct-to-Consumer (DTC) Business Models Impact
Chapter 4. Peptide Type Business Analysis
4.1. U.S. Peptide Therapeutics (Retail Side) Market: Peptide Type Movement Analysis
4.2. U.S. Peptide Therapeutics (Retail Side) Market: Peptide Type Segment Dashboard
4.3. Peptide Type Movement & Market Share Analysis, 2024 & 2033
4.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Peptide Type
4.5. GLP-1 Peptides
4.6. Wellness/Longevity/Healthspan Peptides
4.7. Peptides for Other Acute or Chronic Medical Conditions
Chapter 5. Therapeutics Type Business Analysis
5.1. U.S. Peptide Therapeutics (Retail Side) Market: Therapeutics Type Movement Analysis
5.2. U.S. Peptide Therapeutics (Retail Side) Market: Therapeutics Type Segment Dashboard
5.3. Therapeutics Type Movement & Market Share Analysis, 2024 & 2033
5.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Therapeutics Type
5.5. Innovative (Branded) Peptides
5.6. Biosimilar Peptides
5.7. Generic Peptides
Chapter 6. Indication Business Analysis
6.1. U.S. Peptide Therapeutics (Retail Side) Market: Indication Movement Analysis
6.2. U.S. Peptide Therapeutics (Retail Side) Market: Indication Segment Dashboard
6.3. Indication Movement & Market Share Analysis, 2024 & 2033
6.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Indication
6.5. Type 2 Diabetes
6.6. Obesity / Weight Management
6.7. Neuroendocrine Tumors
6.8. Acromegaly
6.9. Growth Hormone Deficiency
6.10. Prostate Cancer
6.11. Osteoporosis
6.12. Breast Cancer (hormone-sensitive)
6.13. Endometriosis
6.14. Others
Chapter 7. Route of Administration Business Analysis
7.1. U.S. Peptide Therapeutics (Retail Side) Market: Route of Administration Movement Analysis
7.2. U.S. Peptide Therapeutics (Retail Side) Market: Route of Administration Segment Dashboard
7.3. Route of Administration Movement & Market Share Analysis, 2024 & 2033
7.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Route of Administration
7.5. Oral
7.6. Parenteral
7.7. Transdermal
7.8. Nasal
7.9. Other Route of Administration
Chapter 8. Distribution Channel Business Analysis
8.1. U.S. Peptide Therapeutics (Retail Side) Market: Distribution Channel Movement Analysis
8.2. U.S. Peptide Therapeutics (Retail Side) Market: Distribution Channel Segment Dashboard
8.3. Distribution Channel Movement & Market Share Analysis, 2024 & 2033
8.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Distribution Channel
8.5. Offline Retail Pharmacies
8.5.1. Offline Retail Pharmacies Market, 2021-2033 (USD Million)
8.5.2. Chain Pharmacies
8.5.3. Specialty Retail Pharmacies
8.5.4. Independent Community Pharmacies
8.6. Online Pharmacies / Telehealth
8.7. Others (Specialized Peptide Clinics)
Chapter 9. Competitive Landscape
9.1. Company Categorization (Offline Pharmacies)
9.2. Company Categorization (Online Pharmacies)
9.3. Company Categorization (Specialized Hormone Clinics)
9.4. Participant’s Overview
9.4.1. Offline Pharmacies
9.4.2. Online Pharmacies
9.4.3. Specialized Hormone Clinics
9.5. Company Market Position Analysis
9.6. Strategy Mapping
9.6.1. Regional Expansion
9.6.2. Mergers & Acquisitions
9.6.3. Others
9.7. Company Profiles
- Offline Pharmacies:
- CVS Health
- Walgreens Boots Alliance, Inc.
- Walmart Pharmacy
- Rite Aid Corp
- The Kroger Co.
- Albertsons
- Publix
- Costco Wholesale Corporation
- Meijer, Inc.
- Online Pharmacies:
- Hims & Hers Health, Inc
- Ro (Roman Health Ventures Inc.)
- Lemonaid Health, Inc. (acquired by 23andMe in November 2021)
- Mark Cuban Cost Plus Drug Company, PBC
- Amazon.com, Inc.
- Blink Health Administration LLC, Inc.
- GoodRx, Inc
- Honeybee Health Inc.
- TruePill. (acquired by LetsGetChecked in October 2024)
- AgelessRx
- Specialized Hormone Clinics:
- Defy Medical
- Renew Vitality
- Victory Men’s Health
- Hone Health
- Joi & Blokes
- Ways2Well
- 4Ever Young Anti-aging Solutions
- T Clinics USA
For more information about this report visit https://www.researchandmarkets.com/r/691cll
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- U.S. Peptide Therapeutics (Retail Side) Market
